Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 15;11(5):212. doi: 10.21037/atm-23-460

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2023 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Subgroup analysis of progression-free survival in 57 patients with RSTs who underwent combination therapy of anlotinib and camrelizumab. (A) Progression-free survival in subgroups of L-sarcomas (red line) and non-L-sarcomas (blue line) was compared, showing that patients with non-L-sarcoma had a significantly longer mPFS than those with L-sarcoma (11.1 vs. 6.3 months; P=0.0256). (B) Progression-free survival in G1 (red line), G2 (green line), and G3 (blue line) sarcomas were compared, and the mPFS was similar between the FNCLCC grade subgroups (G1 vs. G2 vs. G3: 5.9 vs. 13.5 vs. 6.8 months; P=0.6361). RSTs, retroperitoneal soft tissue sarcomas; mPFS, median progression-free survival; FNCLCC, Fédération Nationale des Centres de Lutte Contre Le Cancer.